Home › Ewing Sarcoma › Georgia › Atlanta
Ewing Sarcoma clinical trials in Atlanta, GA
5 studies for Ewing Sarcoma are looking for participants at sites in and around Atlanta (within about 30 miles). Open a study to see who can join and how to contact the study team.
Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes
RecruitingPhase 1
- Children's Healthcare of Atlanta - Arthur M Blank Hospital (AMBH), Atlanta
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
RecruitingPhase 1
- Emory University - Winship Cancer Institute, Atlanta
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
RecruitingPhase 1/2
- Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta
Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
RecruitingPhase 1/2
- Children's Healthcare of Atlanta/Emory University School of Medicine, Atlanta
Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma
RecruitingPhase 1/2
- Children's Healthcare of Atlanta at Arthur M. Blank Hospital, Atlanta
Ewing Sarcoma trials in other cities
- New York City, NY8 studies
- Houston, TX7 studies
- Philadelphia, PA7 studies
- Memphis, TN7 studies
- Boston, MA6 studies
- Los Angeles, CA6 studies
- Aurora, CO6 studies
- Washington, DC6 studies
- Birmingham, AL5 studies
- Cincinnati, OH4 studies
- Phoenix, AZ4 studies
- Columbus, OH4 studies
Other studies in Atlanta
- Cancer (all types)50 studies
- Non-Small Cell Lung Cancer46 studies
- Breast Cancer41 studies
- Multiple Myeloma41 studies
- Prostate Cancer32 studies
- Lung Cancer29 studies
- Acute Myeloid Leukemia29 studies
- Colorectal Cancer29 studies
- Ovarian Cancer28 studies
- Metastatic Cancer27 studies
- Heart Failure25 studies
- Obesity25 studies
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.